Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 7th. Analysts expect Bio-Techne to post earnings of $0.44 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Bio-Techne Stock Down 3.1 %

NASDAQ:TECH opened at $77.66 on Tuesday. The firm has a market capitalization of $12.24 billion, a P/E ratio of 61.46, a PEG ratio of 8.37 and a beta of 1.29. Bio-Techne has a 1-year low of $51.79 and a 1-year high of $85.85. The company’s fifty day moving average price is $76.25 and its 200-day moving average price is $73.32. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.08 and a quick ratio of 2.88.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TECH. Robert W. Baird increased their target price on shares of Bio-Techne from $73.00 to $81.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Benchmark reaffirmed a “buy” rating and issued a $95.00 target price on shares of Bio-Techne in a report on Thursday, May 2nd. Finally, Citigroup cut shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, May 22nd. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.00.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.